Showing results (1921-1930 of 1,979) with videos related to
Sort By:
Pageof 198
American Journal of Hypertension|August 20, 2013
How many measurements are needed to estimate blood pressure variability without loss of prognostic information?Luis J Mena, Gladys E Maestre, Tine W Hansen, et al.Cardiovascular Diabetology|February 7, 2025
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline WorkshopKatharine Barnard-Kelly, Tadej Battelino, Frank C Brosius, et al.JAMA Cardiology|March 25, 2026
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical TrialSharon L Mulvagh, Silvio E Inzucchi, Nikolaus Marx, et al.Journal of Medicinal Chemistry|December 28, 2020
Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320Thomas B Kjeldsen, František Hubálek, Tina M Tagmose, et al.JAMA|August 7, 2019
Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular OutcomesWen-Yi Yang, Jesus D Melgarejo, Lutgarde Thijs, et al.Hypertension (Dallas, Tex. : 1979)|March 13, 2013
Masked hypertension in diabetes mellitus: treatment implications for clinical practiceStanley S Franklin, Lutgarde Thijs, Yan Li, et al.American Journal of Hypertension|February 9, 2013
Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participantsRudolph Schutte, Lutgarde Thijs, Kei Asayama, et al.Cancer Research|September 28, 2014
Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic propertiesMarie Stampe Ostenfeld, Dennis K Jeppesen, Jens R Laurberg, et al.The Journal of Clinical Endocrinology and Metabolism|July 21, 2026
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?Silvio E Inzucchi, Rohana Abdul Ghani, John Deanfield, et al.Nature Medicine|August 29, 2017
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligandLinda Yang, Chih-Chuan Chang, Zhe Sun, et al.Pageof 198